Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Take a brief audio tour around Scrip's Five Must-Know Things, this time for the business week ended 16 October 2020. 

In this edition we take a look at progress and setbacks with coronavirus vaccines, a major deal in liver disease, one company's plans in immunology, and prospects for the global oncology market.


These and other Informa Pharma Intelligence podcasts are available on SoundCloud and Apple Podcasts.

Stories mentioned in this episode:

(Also see "Pfizer’s First COVID-19 Vaccine Results Might Be Just Days Away - But Patience Could Pay Off" - Scrip, 14 Oct, 2020.)

(Also see "J&J Says It's Wait And See On COVID-19 Vaccine Delay, Outlines Rosier Outlook for 2021" - Scrip, 13 Oct, 2020.)

(Also see "$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions" - Scrip, 9 Oct, 2020.)

(Also see "BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis" - Scrip, 12 Oct, 2020.)

(Also see "R&D Trends Driving Broad Change In Surging Oncology Sector" - Scrip, 9 Oct, 2020.)

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts